Arcangeli G, Micheli A, D'Angelo L, Giovinazzo G, Arcangeli G, Tersigni R, Comandini E, Scala T, Lopez M, Mauri M, D'Aprile M
Radiation Oncology Centre, S. Maria Goretti Hospital, Latina, Italy.
Radiother Oncol. 1998 Jan;46(1):39-45. doi: 10.1016/s0167-8140(97)00109-6.
This study analyses and compares the results of local regional control, distant metastases and survival in two series of patients irradiated from 1986 to 1992 in our radiation oncology centre following quadrantectomy or tumourectomy for early stage breast cancer.
The quadrantectomy group consisted of 152 women, 109 (72%) with T1 and 43 (28%) with T2 tumours. Axillary nodes in this group were positive in 51 (33%) patients. The tumourectomy group included 123 women, 71 (58%) with T1 and 52 (42%) with T2 tumours. Positive axillary nodes were found in 56 (46%) of these patients. All quadrantectomy and tumourectomy patients received a dose of 50 Gy in 5 weeks to the whole breast, followed by a 10-16 Gy electron boost. Node positive patients in the tumourectomy group also received 50 Gy to the axillary apex and supraclavicular region. In both surgical groups, node positive premenopausal and postmenopausal patients received adjuvant CMF or tamoxifen therapy, respectively.
After a median follow-up of 58 months, 89% of women in the tumourectomy group and 87% in the quadrantectomy group were alive and 80 and 73%, respectively, were free of disease. Breast and nodal failures were detected in 4.9 and 0.8% of cases, respectively, in the tumourectomy group, as compared to 5.9 and 3.3% of cases, respectively, in the quadrantectomy group. Distant relapses were observed in 16 and 18% of patients in the former and latter groups, respectively. Actuarial overall and disease-free survival was similar in the two series, with 5-year rates of 90 and 72%, respectively, in the tumourectomy group, and of 91 and 78%, respectively, in the quadrantectomy group. The differences in survival are not statistically different.
Our findings show that tumourectomy and quadrantectomy, followed by adequate radiotherapy, provide comparable results in terms of local-regional control and survival.
本研究分析并比较了1986年至1992年在我们放射肿瘤中心接受象限切除术或肿瘤切除术治疗早期乳腺癌后接受放疗的两组患者的局部区域控制、远处转移和生存结果。
象限切除术组由152名女性组成,其中109名(72%)为T1期肿瘤,43名(28%)为T2期肿瘤。该组51名(33%)患者腋窝淋巴结阳性。肿瘤切除术组包括123名女性,其中71名(58%)为T1期肿瘤,52名(42%)为T2期肿瘤。这些患者中有56名(46%)腋窝淋巴结阳性。所有象限切除术和肿瘤切除术患者均在5周内接受全乳50 Gy的剂量,随后进行10 - 16 Gy的电子束加量照射。肿瘤切除术组中淋巴结阳性的患者还接受了腋窝尖和锁骨上区域50 Gy的照射。在两个手术组中,淋巴结阳性的绝经前和绝经后患者分别接受辅助CMF或他莫昔芬治疗。
中位随访58个月后,肿瘤切除术组89%的女性存活,象限切除术组87%的女性存活,分别有80%和73%的患者无疾病。肿瘤切除术组分别有4.9%和0.8%的病例检测到乳腺和淋巴结复发,而象限切除术组分别为5.9%和3.3%。前一组和后一组分别有16%和18%的患者出现远处复发。两个系列的精算总生存率和无病生存率相似,肿瘤切除术组5年生存率分别为90%和72%,象限切除术组分别为91%和78%。生存差异无统计学意义。
我们的研究结果表明,肿瘤切除术和象限切除术,随后进行适当的放疗,在局部区域控制和生存方面提供了可比的结果。